We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

Mark Reilly, the former head of GSK’s China operations, was given a three year prison sentence - suspended for four years - and will be deported. Other GSK staff have also been sentenced, according to ...

The Changsha court also on Friday sentenced British national Mark Reilly, the former head of GSK's China operations, and an unstated number of other company officials to between two to four years ...

GlaxoSmithKline is in a spree of producing new diabetes and cancer drugs which it hopes will increase its sales this year. After the recent U.S. drug approvals it is starting to market two of its ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GlaxoSmithKline (GSK) has released an update. GlaxoSmithKline (GSK) has announced that its issued share capital as of October 31, 2024, consists of over 4.3 billion ordinary shares, with a total ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

The Drugs Controller General of India (DGCI) has granted approval to Sanofi and Glaxo Smith Kline (GSK) to conduct Phase-III clinical study, to assess the safety, efficacy and immunogenicity of ...

On October 15, 2024, GSK filed two complaints against Moderna in the District Court for the District of Delaware, asserting that Moderna willfully infringes GSK’s mRNA patent portfolio.